Clean Yield Group Has $1.68 Million Holdings in Amgen Inc. (NASDAQ:AMGN)

Clean Yield Group lessened its stake in Amgen Inc. (NASDAQ:AMGN) by 10.1% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 5,399 shares of the medical research company’s stock after selling 609 shares during the quarter. Clean Yield Group’s holdings in Amgen were worth $1,682,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in the stock. Sivia Capital Partners LLC boosted its holdings in shares of Amgen by 4.5% in the first quarter. Sivia Capital Partners LLC now owns 1,072 shares of the medical research company’s stock valued at $334,000 after buying an additional 46 shares during the period. Gemmer Asset Management LLC boosted its holdings in shares of Amgen by 3.4% in the first quarter. Gemmer Asset Management LLC now owns 1,390 shares of the medical research company’s stock valued at $433,000 after buying an additional 46 shares during the period. Godsey & Gibb Inc. boosted its holdings in shares of Amgen by 2.0% in the first quarter. Godsey & Gibb Inc. now owns 66,003 shares of the medical research company’s stock valued at $20,563,000 after buying an additional 1,285 shares during the period. KFG Wealth Management LLC boosted its holdings in shares of Amgen by 6.6% in the first quarter. KFG Wealth Management LLC now owns 3,463 shares of the medical research company’s stock valued at $1,079,000 after buying an additional 214 shares during the period. Finally, Butensky & Cohen Financial Security Inc. boosted its holdings in shares of Amgen by 0.3% in the first quarter. Butensky & Cohen Financial Security Inc. now owns 16,295 shares of the medical research company’s stock valued at $5,077,000 after buying an additional 47 shares during the period. Institutional investors and hedge funds own 76.50% of the company’s stock.

Insider Transactions at Amgen

In other news, SVP Rachna Khosla sold 1,500 shares of the firm’s stock in a transaction dated Thursday, June 5th. The shares were sold at an average price of $289.68, for a total transaction of $434,520.00. Following the completion of the sale, the senior vice president now owns 8,162 shares in the company, valued at approximately $2,364,368.16. This trade represents a 15.52% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 0.76% of the stock is currently owned by corporate insiders.

Amgen Stock Performance

NASDAQ AMGN opened at $290.33 on Friday. The firm has a 50-day moving average of $281.57 and a 200-day moving average of $285.42. The company has a debt-to-equity ratio of 9.62, a quick ratio of 0.95 and a current ratio of 1.26. The stock has a market cap of $156.11 billion, a PE ratio of 38.45, a P/E/G ratio of 2.63 and a beta of 0.51. Amgen Inc. has a 52-week low of $253.30 and a 52-week high of $346.85.

Amgen (NASDAQ:AMGN) last posted its earnings results on Thursday, May 1st. The medical research company reported $4.90 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.18 by $0.72. The company had revenue of $8.15 billion during the quarter, compared to analysts’ expectations of $8.05 billion. Amgen had a net margin of 12.24% and a return on equity of 176.32%. Amgen’s quarterly revenue was up 9.4% compared to the same quarter last year. During the same quarter last year, the company posted $3.96 EPS. On average, sell-side analysts anticipate that Amgen Inc. will post 20.62 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on AMGN shares. Bank of America increased their target price on shares of Amgen from $275.00 to $294.00 and gave the stock an “underperform” rating in a report on Wednesday, March 5th. Erste Group Bank cut shares of Amgen from a “strong-buy” rating to a “hold” rating in a report on Thursday, May 8th. Guggenheim started coverage on shares of Amgen in a report on Tuesday, May 20th. They set a “neutral” rating and a $288.00 target price for the company. UBS Group restated a “neutral” rating and set a $315.00 target price (down previously from $319.00) on shares of Amgen in a report on Friday, May 2nd. Finally, Morgan Stanley restated an “equal weight” rating on shares of Amgen in a report on Friday, May 2nd. Two research analysts have rated the stock with a sell rating, twelve have issued a hold rating, nine have assigned a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, Amgen presently has an average rating of “Hold” and a consensus target price of $309.22.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.